"Investigation of the Relationship Between New Coronary Virus Disease (COVID-19) and Anxiety and Depressive Symptoms in Pregnant Women"

• Sponsor: Kanuni Sultan Suleyman Training and Research Hospital (Other)
• Overall Status: Completed
• CT.gov ID: NCT04384887
• Collaborator: Ayşegül Bestel (Other), İbrahim Polat (Other), Merve Aldıkaçtıoğlu Talmaç (Other)
• Enrollment: 100
• Location: 1
• Actual Duration (Months): 4
• Patients Per Site Per Month: 24.7

Study Details

Study Description

Brief Summary

In our study; Anxiety and depression levels, socio-demographic characteristics of the pregnant women who were admitted to our hospital between 25.04.2020-25.07.2020 and treated with the diagnosis of covid 19, and the change in anxiety and depression levelsWİTH Beck Depression and Anxiety Score after the disease regressed are planned.

(Beck depression scale contains 10 questions and a total of 1 to 100 points is obtained. High score indicates that depression and anxiety are high.) 0-16 points = mild depressive symptoms

17-29 points = moderate depressive symptoms

30-63 points = severe depressive symptoms

Condition or Disease	Intervention/Treatment	Phase
COVID; Anxiety; Depression, Postpartum	Behavioral: covid-19 positive pregnant women

Detailed Description

The sociodemographic data form prepared by the researchers will be filled out by interviewing the patients who are willing to participate in the study. In addition, Beck Depression Scale, Beck Anxiety Scale, State and Trait Anxiety Scale will be given by the participants themselves. When the patients come to their first control after discharge, the scales specified will be repeated.

Study Design

• Study Type: Observational
• Actual Enrollment: 100 participants
• Observational Model: Case-Control
• Time Perspective: Prospective
• Official Title: ''(COVID-19) and Anxiety and Depressive Symptoms in Pregnant Women"
• Actual Study Start Date: Apr 25, 2020
• Actual Primary Completion Date: Aug 25, 2020
• Actual Study Completion Date: Aug 26, 2020

Outcome Measures

Primary Outcome Measures

1. Evaluation of depression and anxiety score changes of covid-19 positive pregnants [4 months]

   Evaluation of depression and anxiety score changes of covid-19 positive pregnants Pregnant women are questioned how this period was affected, as the pandemic period loaded with extra stress and caused depression and anxiety.

Eligibility Criteria

Criteria

• Ages Eligible for Study: 18 Years to 45 Years
• Sexes Eligible for Study: Female
• Accepts Healthy Volunteers: Yes

Inclusion Criteria:

• covid -19 pcr positive pregnant women

• no psychiatric diagnosis no use of psychiatric medicine

Exclusion Criteria:

Non-pregnant patients, A psychiatric diagnosis use of psychiatric medicine

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	Pinar Yalcin Bahat	Istanbul	İ̇stanbul	Turkey	34000

Sponsors and Collaborators

• Kanuni Sultan Suleyman Training and Research Hospital
• Ayşegül Bestel
• İbrahim Polat
• Merve Aldıkaçtıoğlu Talmaç

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.

• Responsible Party: Pınar Yalcin bahat, Principal Investigator, Kanuni Sultan Suleyman Training and Research Hospital
• ClinicalTrials.gov Identifier: NCT04384887
• Other Study ID Numbers: beckcovid
• First Posted: May 12, 2020
• Last Update Posted: Sep 2, 2020
• Last Verified: May 1, 2020

• Individual Participant Data (IPD) Sharing Statement: Yes
• Plan to Share IPD: Yes
• Studies a U.S. FDA-regulated Drug Product: No
• Studies a U.S. FDA-regulated Device Product: No
• Additional relevant MeSH terms: Depression, Postpartum; Depression; Anxiety Disorders

Study Results

No Results Posted as of Sep 2, 2020